bevacizumab   Click here for help

GtoPdb Ligand ID: 6771

Synonyms: Avastin® | rhuMAb-VEGF
Approved drug
bevacizumab is an approved drug (FDA (2004), EMA (2005))
Compound class: Antibody
Comment: Vascular endothelial growth factor A inhibitor.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Biosimilars: Amgen's bevacizumab-awwb (Mvasi®) was the first bevacizumab biosimilar to be FDA approved. This and others are listed in the table below.
NameTrade nameCompanyClinical PhaseIndications
bevacizumab-awwbMvasiAmgenApproved (FDA 2017)Approved to treat a range of cancers, including certain colorectal, lung, brain, kidney and cervical cancers.
bevacizumab-bvzr; PF-06439535ZirabevPfizerApproved (EMA & FDA 2019)Approved to treat a range of cancers, including certain colorectal, lung, brain, kidney, cervical and breast cancers, plus recurrent glioblastoma (FDA).
SB8AybintioSamsung BioepisApproved (EMA 2020)Approved to treat a range of advanced solid tumour types, in combination with a number of chemotherapeutic drugs.
FKB238EquidacentCentus BiotherapeuticsApproved (EMA 2020)Approved to treat a range of advanced solid tumour types, in combination with a number of chemotherapeutic drugs.
bevacizumab; MYL-1402OAbevmyMylanApproved (EMA 2021)As per originator reference product.
bevacizumabAlymsysMabxience Research/Zentiva Approved (EMA 2021)As per originator reference product.
bevacizumab-maly; BEVZ92-MB02Oyavas; AlymsysSTADA Arzneimittel; Amneal PharmaceuticalsApproved (EMA 2021; FDA 2022)As per originator reference product: NOT adjuvant treatment of colon cancer
bevacizumabOnbevziSamsung Bioepis/BiogenApproved (EMA 2021)As per originator reference product
bevacizumab-adcd; CT-P16VegzelmaCelltrionApproved (EMA & FDA 2022)Approved to treat a range of advanced solid tumours in combination with other cancer drugs: Colorectal, breast, ovarian, fallopian tube, peritoneal, and uterine neoplasms, non-small cell lung cancer, and renal cell carcinoma
CBT124 Cipla BioTechPhase 3
No information available.
Summary of Clinical Use Click here for help
Used as part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer. In August 2014 the US FDA granted additional approval for metastatic cervical cancer. In November 2014, FDA approval was extended to include a combination therapy of bevacizumab plus chemotherapy (paclitaxel, pegylated liposomal doxorubicin or topotecan) for platinum-resistant, recurrent ovarian cancer (based on findings from the Phase 3 AURELIA clinical trial NCT00976911). Additional Phase 2 clinical trial results are provided in [5]. In June 2018, FDA approval was further expanded to include the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, in patients with stage III or IV disease, and to be used after initial surgical resection [2] [4].
Clinical trials evaluating bevacizumab in combination with the immune checkpoint inhibitors ipilimumab (anti-CTLA4) or nivolumab (anti-PD-1) in advanced solid malignancies are underway (for example NCT01950390- Phase 2 stage III-IV melanoma; NCT01454102- Phase 1 stage IIIB/IV non-small cell lung cancer).

A re-engineered version of bevacizumab with a different glycosylation profile (bevacizumab beta, ABP 215) is in Phase 3 clinical trial for metastatic non-small cell lung cancers (NSCLC), This trial, NCT01966003 is comparing bevacizumab beta vs. the original bevacizumab,
Bevacizumab (Avastin®) is sometimes prescribed 'off-label' as a therapy for wet age-related macular degeneration (AMD), as an alternative to ranibizumab (Lucentis®) and aflibercept (Eylea®).

SARS-CoV-2 and COVID-19: Bevacizumab has been entered into clinical trials in patients with COVID-19, to determine if suppression of vascular permeability will reduce pulmonary edema in severe/critical COVID-19 patients.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) which reduces or prevents angiogenesis. The rationale behind anti-VEGF as an anti-angiogenic therapy is described in [3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00976911 AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer Phase 3 Interventional Hoffmann-La Roche
NCT01454102 Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) Phase 1 Interventional Bristol-Myers Squibb
NCT01950390 Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Phase 2 Interventional National Cancer Institute (NCI)
NCT01966003 Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer Phase 3 Interventional Amgen
NCT04275414 Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia Phase 2/Phase 3 Interventional Qilu Hospital of Shandong University Bevacizumab is being evaluated as a mechanism to suppress vascular permeability and pulmonary edema in patients with severe/critical COVID-19. This anti-VEGF drug is predicted to reduce acute lung injury and acute respiratory distress syndrome (ARDS) in selected patients, and hopefully to reduce respiratory failure and death from COVID-19.
NCT04344782 Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort Phase 2 Interventional Assistance Publique - Hôpitaux de Paris
NCT04305106 Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT N/A Interventional Qilu Hospital of Shandong University
External links Click here for help